Campbell Heather M, Murata Allison E, Mao Jenny T, McMahon Benjamin, Murata Glen H
VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM 87106, USA.
College of Pharmacy, University of New Mexico, Albuquerque, NM 87131-0001, USA.
Biol Methods Protoc. 2022 Aug 4;7(1):bpac017. doi: 10.1093/biomethods/bpac017. eCollection 2022.
Many mathematical models have been proposed to predict death following the Coronavirus Disease 2019 (COVID-19); all started with comorbidity subsets for this still-little understood disease. Thus, we derived a novel predicted probability of death model (PDeathDx) upon all diagnostic codes documented in the Department of Veterans Affairs. We present the conceptual underpinnings and analytic approach in estimating the independent contribution of pre-existing conditions. This is the largest study to-date following patients with COVID-19 to predict mortality. Cases were identified with at least one positive nucleic acid amplification test. Starting in 1997, we use diagnoses from the first time a patient sought care until 14 days before a positive nucleic acid amplification test. We demonstrate the clear advantage of using an unrestricted set of pre-existing conditions to model COVID-19 mortality, as models using conventional comorbidity indices often assign little weight or usually do not include some of the highest risk conditions; the same is true of conditions associated with COVID-19 severity. Our findings suggest that it is risky to pick comorbidities for analysis without a systematic review of all those experienced by the cohort. Unlike conventional approaches, our comprehensive methodology provides the flexibility that has been advocated for comorbidity indices since 1993; such an approach can be readily adapted for other diseases and outcomes. With our comorbidity risk adjustment approach outperforming conventional indices for predicting COVID-19 mortality, it shows promise for predicting outcomes for other conditions of interest.
许多数学模型已被提出用于预测2019年冠状病毒病(COVID-19)后的死亡情况;所有模型都从这种仍知之甚少的疾病的合并症子集入手。因此,我们根据退伍军人事务部记录的所有诊断代码推导了一种新的死亡预测概率模型(PDeathDx)。我们介绍了估计既往疾病独立贡献的概念基础和分析方法。这是迄今为止跟踪COVID-19患者以预测死亡率的最大规模研究。通过至少一次核酸扩增检测呈阳性来确定病例。从1997年开始,我们使用患者首次寻求治疗直至核酸扩增检测呈阳性前14天的诊断信息。我们证明了使用不受限制的既往疾病集来模拟COVID-19死亡率的明显优势,因为使用传统合并症指数的模型往往权重较小,或者通常不包括一些最高风险的疾病;与COVID-19严重程度相关的疾病也是如此。我们的研究结果表明,在没有对队列中所有经历的疾病进行系统回顾的情况下选择合并症进行分析是有风险的。与传统方法不同,我们的综合方法提供了自1993年以来一直倡导的合并症指数的灵活性;这种方法可以很容易地适用于其他疾病和结局。由于我们的合并症风险调整方法在预测COVID-19死亡率方面优于传统指数,它在预测其他相关疾病的结局方面显示出前景。